Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VMX-COO1

            Therapeutic Area: Hematology Product Name: VMX-COO1

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $36.6 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 08, 2020

            Details:

            Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.